Detail akcie IN8bio Rg online

Business Summary: IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, IN8bio Inc revenues was not reported. Net loss decreased 40% to $14.5M. Lower net loss reflects Research and development decrease of 51% to $5.8M (expense), General and administrative decrease of 31% to $5.6M (expense), Stock-based Compensation in R&D decrease of 44% to $862K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$16.16 to -$4.08.